Modern and stylish animation production for a pharma company pioneering in interventional medicine.
This excerpt from the 3D animation created for BTG's interventional oncology drug called DC Bead®, explains how chemoembolization (also called transartertial chemoembolization or TACE) is used in the treatment of primary liver cancer or hepatocellular carcinoma (HCC) with the use of drug-eluting beads.
Web + Online Images
BTG Plc, Biocompatibles
Our brief was to develop a modern and stylish vision of Biocompatibles' DC bead product animation. We achieved this through effective storytelling, showcased the mechanism-of-action (MoA) of DC Bead® - how the drug is administered to patients via a minimally invasive procedure, and how it effectively embolizes the tumor in the liver.
The use of motion graphics aid in highlighting the clinical findings and evidence-based research data from scientific experts, and compliments the messaging of the MoA.
Liver cancer is the growth and spread of unhealthy cells in the liver.
The two types of cancerous tumors that can occur in the liver are primary liver cancer and secondary liver cancer. Primary liver cancer is defined as the original site (organ or tissue) where cancer began.
Secondary liver cancer, which is cancer that has spread (metastasized) to the liver from other organs, such as the colon or pancreas. These cancer cells are carried in the bloodstream or lymphatic system to another part of the body. The cells may stay in that part of the body and make a new tumour.
Marketing Communications, Interventional Medicine, BTG Plc, Biocompatibles, London, UK
Breakthrough cancer pain
MoA video for a U.S. product launch of a breakthrough oncology drug.
+44 (0) 20 7183 9412 - UK
+1 646 568 4358 - USA
Suite 6, Claremont House,
22-24, Claremont Rd.,
KT6 4QU, UK